Curis, Inc. appointed Diantha Duvall to the position of chief financial officer, treasurer, assistant secretary, principal financial officer and principal accounting officer of the Company effective as of August 5, 2022. Ms. Duvall, age 51, joined the Company on July 26, 2022 as senior vice president of strategy. Ms. Duvall previously served as chief financial officer of Genocea Biosciences, Inc., a biotechnology company focused on the development of neoantigen cancer immunotherapies, from March 2019 to July 2022.

Prior to that, Ms. Duvall served as vice president, finance and chief accounting officer at Bioverativ, Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, from February 2017 to January 2019. Prior to joining Bioverativ, Inc., Ms. Duvall was global commercial controller and U.S. commercial controller at Biogen, Inc. in 2016 and 2015, respectively. Prior to Biogen, Inc., Ms. Duvall held a number of positions of increasing responsibility at Merck and Co., Inc. from 2009 to 2015.

Ms. Duvall holds a B.A. in economics and public policy from Colby College and an M.S. in accounting and MBA from Northeastern University.